In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively suppresses production of the virus in chronically infected cells, and prevents viral rebound, even when those infected cells are subjected to vigorous stimulation.
The study, led by TSRI Associate Professor Susana Valente, was published online Oct. 17 before print in the journal Cell Reports.
“No other anti-retroviral used in the clinic today is able to completely suppress viral production in infected cells in vivo,” Valente said. “When combining this drug with the standard cocktail of anti-retrovirals used to suppress infection in humanized mouse models of HIV-1 infection, our study found a drastic reduction in virus RNA present—it is really the proof-of-concept for a ‘functional cure.’”
Valente, a pioneer in this new approach, calls it “Block-and-Lock”—the approach blocks reactivation of the virus in cells, even during treatment interruptions, and locks HIV into durable state of latency.
Valente and her colleagues use a derivative of a natural compound called didehydro-Cortistatin A (dCA), which blocks replication in HIV-infected cells by inhibiting the viral transcriptional activator, called Tat, halting viral production, reactivation and replenishment of the latent viral reservoir.
“Combining dCA with anti-retroviral therapy accelerates HIV-1 suppression and prevents viral rebound after treatment interruption, even during strong cellular activation,” Valente said. “It’s important to note that our study uses the maximum tolerable dose of the drug—with virtually no side effects.”
The scientists studied the combination therapy in a mouse model of HIV latency and persistence. Once the combined treatment regimen was halted, viral rebound was delayed up to 19 days, compared with just seven days in mouse models receiving only anti-retroviral treatment.
“This demonstrates the potential of ‘block-and-lock’ strategies,” said TSRI Research Associate Cari F. Kessing, co-first author of the study. “This study shows that a ‘functional cure’ approach can succeed in reducing residual virus in the blood during anti-retroviral treatment and limiting viral rebound during treatment interruption.”
“In half of the dCA treated mice, the virus was undetectable for 16 days after all treatment was halted,” said the University of North Carolina’s Christopher Nixon, another first author.
“We blocked Tat, and the cell’s machinery did the rest,” said TSRI Research Associate Chuan Li, a coauthor of the study. “The result was that the HIV promoter becomes repressed.”
Valente pointed out that the animal models were exposed to just a single month of treatment. “That’s a relatively short period of time,” she said. “We think longer treatments will result in longer, or even permanent, rebound delays. The question is how long? We’re studying that now.”
Because any viral rebound of HIV comes with a host of adverse effects, Valente noted, blocking that rebound would automatically reduce those effects.
“This is the only class of drugs that stops infected cells from making viruses outright,” said Valente. “All current antivirals work later in the viral lifecycle, so only a HIV transcriptional inhibitor like dCA can stop the side effects of low-level virus production.”
The Latest on: HIV
- HIV CARE PROVIDERS IDENTIFY THE TOP BARRIERS TO ENDING THE EPIDEMICon December 11, 2019 at 4:26 pm
Washington, DC, Dec. 11, 2019 (GLOBE NEWSWIRE) -- The American Academy of HIV Medicine (AAHIVM), today, highlighted critical barriers to ending the HIV epidemic as identified by HIV care providers in ...
- HIV Vaccine in 2021? Leading Experts ‘Optimistic’ About Ongoing Trialson December 11, 2019 at 3:13 pm
On Sunday, World AIDS Day, the global fight against the human immunodeficiency virus is poised to make important advances thanks to three experimental HIV vaccines that are entering the final stages ...
- Efforts to end the HIV epidemic must not ignore people already living with HIVon December 11, 2019 at 8:43 am
Efforts to prevent new HIV transmissions in the United States must be accompanied by advances in addressing HIV-associated comorbidities to improve the health of people already living with HIV, ...
- Vesicles released by bacteria may reduce the spread of HIV in human tissueson December 11, 2019 at 2:55 am
Nano-sized vesicles released by certain bacteria that inhabit the vagina may protect against HIV infection, suggests a study of human cells and tissues by researchers at the National Institutes of ...
- Extracellular vesicles from symbiotic vaginal lactobacilli inhibit HIV-1 infection of human tissueson December 11, 2019 at 2:14 am
The vaginal microbiota, dominated by Lactobacillus spp., plays a key role in preventing HIV-1 transmission. Here, we investigate whether the anti-HIV effect of lactobacilli is mediated by ...
- Cleveland’s HIV/AIDS program failed to test highest risk populations, reach out to exposed partners quicklyon December 10, 2019 at 1:00 pm
The state in a November email to the city said deadlines were missed for executing the contracts and filling the positions. City health officials have touted the decline of newly diagnosed HIV ...
- Newly proposed model for shape of HIV-1 viral shell may change how we understand the diseaseon December 10, 2019 at 6:40 am
The shell of the HIV-1 virus may have a different shape than previously thought, according to a new study by University of Alberta that has significant implications for understanding how the virus ...
- Fifty-Two Public Health Groups Demand Facebook Remove Latest Round of 'Frightening' HIV Adson December 9, 2019 at 11:52 am
Fifty-two public health companies and LGBTQ organizations wrote a public letter to Facebook Monday demanding it remove misleading advertisements about HIV prevention medicine. The posts imply that HIV ...
- Making HIV drugs free doesn’t help people with no accesson December 9, 2019 at 11:31 am
The Trump administration announced last week a new program that will provide HIV prevention medications free of charge for uninsured patients. These pre-exposure prophylaxis (or PrEP) drugs are highly ...
- LGBTQ groups accuse Facebook ads of spreading misinformation about HIV drugson December 9, 2019 at 10:22 am
A coalition of 50 LGBTQ, HIV/AIDS and public health groups on Monday sent a letter to Facebook accusing the social media giant of allowing ads to run on the platform with dangerous misinformation ...
via Google News and Bing News